Excellergy develops immunology-based therapies focused on treating allergic diseases through novel biologic drug candidates.
Excellergy has raised $70.0M in total funding. The most recent round was Series A. The last funding was announced in October 2025.
Excellergy's investors include Samsara BioCapital, Decheng Capital, Red Tree Venture Capital.
Excellergy is headquartered in Palo Alto, United States.
Excellergy develops immunology-based therapies focused on treating allergic diseases through novel biologic drug candidates.
Excellergy is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Excellergy — Funding & Investors." VCBacked, October 13, 2025, https://www.vcbacked.co/company/excellergy. Accessed August 14, 2026.
VCBacked. (2025). Excellergy — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/excellergy
{{cite web |title=Excellergy — Funding & Investors |url=https://www.vcbacked.co/company/excellergy |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated